At the moment, Leqembi is administered intravenously at clinics every two weeks, although, in January Eisai and Biogen were ...

Aiming to deliver blockbuster sales of its Alzheimer’s disease-fighting antibody Leqembi in its 2027 fiscal year, Eisai has cleared a key regulatory hurdle in its quest to grow the medicine's reach | ...

Biogen has taken a step to “significantly refresh” its board of directors, departing chair Stelios Papadopoulos, Ph.D., said. But the reported romantic relationship between a new nominee and a ...

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the ...

With this in mind, let’s take a look at the high growth pharma stocks that are profitable in 2025. We filtered stocks using a screener, applying criteria of five-year revenue growth exceeding 25% and ...

Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday. The investment would go toward growing the drugmaker’s ...

Cambridge, Mass.-based Biogen entered a licensing agreement with Forward Pharma for the Danish drugmaker's multiple sclerosis treatments.